ArticleJournal of forensic sciences2026
Determination of mitragynine concentrations in medicolegal death investigations at the Oklahoma Office of the Chief Medical Examiner from 2022 to 2023.
Article in Journal of forensic sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Kratom-Associated Pulmonary Toxicity: A Systematic Review of Case Reports and Forensic Series with a Proposed Clinical Phenotype Classification.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of mitragynine, the major psychoactive component in kratom, has increased in forensic toxicology casework due to its current legal status and ease of accessibility in local shops and the online community. This study presents 28 death investigation cases from 2022 to 2023 in Oklahoma including mitragynine concentrations alongside case demographics, pathological findings, and additional toxicological results. Quantitative results for mitragynine in heart blood, femoral blood, and liver were obtained by liquid chromatography/tandem mass spectrometry (LC/MS-MS) following supported liquid extraction. Postmortem heart blood concentrations ranged from 130 to 2600 ng/mL with a mean of 735 ng/mL and a median of 550 ng/mL. Postmortem femoral blood concentration ranged from 130 to 7500 ng/mL with a mean of 900 ng/mL and a median of 570 ng/mL. Postmortem redistribution ratios were determined for 25 cases that had paired central and peripheral samples (range 0.31-1.86) and for 20 cases that had paired peripheral and liver samples (range 0.86-9.70). Overall central to peripheral and liver to peripheral ratios suggest mitragynine exhibits minimal postmortem redistribution, although a few individual cases demonstrated variability. Twenty-two cases listed mitragynine in the cause of death with 21 of those cases including at least one other drug detected and reported on the death certificate. The data presented shows the importance of quantifying mitragynine in medicolegal death investigations to aid in cause and manner of death determination.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.